tiprankstipranks
Trending News
More News >
Biomerica Inc (BMRA)
NASDAQ:BMRA
US Market
Advertisement

Biomerica (BMRA) AI Stock Analysis

Compare
406 Followers

Top Page

BMRA

Biomerica

(NASDAQ:BMRA)

Rating:49Neutral
Price Target:
$3.00
▼(-15.01%Downside)
Biomerica's overall stock score is primarily impacted by its financial challenges, including declining revenues and persistent losses. Technical analysis indicates a bearish trend, while valuation metrics are weak due to negative earnings. The recent corporate event involving a key board appointment is a positive factor, potentially improving governance and strategic direction.

Biomerica (BMRA) vs. SPDR S&P 500 ETF (SPY)

Biomerica Business Overview & Revenue Model

Company DescriptionBiomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
How the Company Makes MoneyBiomerica generates revenue primarily through the sale of its diagnostic and therapeutic products. The company offers a range of products targeting various medical conditions, which are sold to laboratories, hospitals, and healthcare providers. Key revenue streams include the sales of diagnostic test kits for food intolerance and gastrointestinal disorders, which are distributed both domestically and internationally. Biomerica also engages in partnerships and collaborations with other healthcare organizations and research institutions to enhance product development and expand market reach. The company aims to leverage its innovative product pipeline and global distribution network to drive sales and increase market share.

Biomerica Financial Statement Overview

Summary
Biomerica faces significant financial challenges with declining revenues and persistent losses impacting profitability and cash flow. The balance sheet is relatively stable, but reliance on external financing and negative cash flows pose risks. Strategic improvements in operational efficiency and revenue growth are needed.
Income Statement
45
Neutral
Biomerica has experienced a decline in revenue over the past years, with a significant drop from 2022 to 2023. The gross profit margin is low, indicating high production costs relative to revenue. The company has been operating at a loss, with negative EBIT and EBITDA margins, suggesting operational inefficiencies. However, there is a slight improvement in net income from 2023 to 2024, indicating potential for recovery.
Balance Sheet
55
Neutral
The balance sheet shows a moderate debt-to-equity ratio, suggesting manageable leverage levels. The equity ratio is relatively healthy, indicating a solid capital structure. However, the declining stockholders' equity over the years is a concern. The return on equity is negative due to consistent net losses, highlighting profitability challenges.
Cash Flow
40
Negative
Biomerica's cash flow statement reveals negative operating cash flow, indicating cash outflows from core operations. The free cash flow is also negative, reflecting challenges in generating cash after capital expenditures. The company has relied on financing activities to support cash needs, which may not be sustainable long-term.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue5.42M5.34M18.87M7.20M6.69M
Gross Profit611.00K446.00K2.98M496.98K1.78M
EBITDA-5.99M-6.74M-3.94M-7.06M-2.27M
Net Income-5.98M-7.14M-4.53M-6.47M-2.34M
Balance Sheet
Total Assets9.25M14.45M11.37M11.82M17.26M
Cash, Cash Equivalents and Short-Term Investments4.17M9.72M5.92M4.20M8.64M
Total Debt785.00K1.08M1.38M1.62M1.78M
Total Liabilities2.66M2.73M3.05M2.59M3.05M
Stockholders Equity6.59M11.72M8.32M9.23M14.21M
Cash Flow
Free Cash Flow-5.48M-5.55M-650.87K-5.55M-4.42M
Operating Cash Flow-5.36M-5.47M-480.53K-5.25M-4.30M
Investing Cash Flow-115.00K-78.00K-170.34K-295.58K-118.93K
Financing Cash Flow-81.00K9.39M2.39M1.11M12.37M

Biomerica Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3.53
Price Trends
50DMA
3.31
Positive
100DMA
3.88
Negative
200DMA
3.67
Negative
Market Momentum
MACD
0.04
Negative
RSI
58.55
Neutral
STOCH
75.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRA, the sentiment is Positive. The current price of 3.53 is above the 20-day moving average (MA) of 3.27, above the 50-day MA of 3.31, and below the 200-day MA of 3.67, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 58.55 is Neutral, neither overbought nor oversold. The STOCH value of 75.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BMRA.

Biomerica Risk Analysis

Biomerica disclosed 32 risk factors in its most recent earnings report. Biomerica reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
The Company is not currently in compliance with the continued listing requirements for The Nasdaq Stock Market. If the Company does not regain compliance and continue to meet the continued listing requirements, our Common Stock may be delisted, which could affect the market price and liquidity for the Company's Common Stock and reduce the Company's ability to raise additional capital. Q2, 2024
2.
Although our financial statements have been prepared on a going concern basis, our current level of cash and cash equivalents available to us is not sufficient to meet our operating plans for the next 12 months, raising substantial doubt regarding our ability to continue as a going concern. Q2, 2024

Biomerica Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
$32.39M-450.47%9.47%81.37%
54
Neutral
$10.26M0.84-499.57%-33.92%
49
Neutral
$8.99M-72.70%5.05%26.13%
48
Neutral
$8.57M-151.23%3.30%31.84%
46
Neutral
C$200.02M-3.36-23.14%1.86%20.75%-0.36%
45
Neutral
$9.43M-45.38%-48.61%32.18%
41
Neutral
$9.92M-56.80%-91.22%11.84%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BMRA
Biomerica
3.53
0.75
26.98%
SSKN
Strata Skin Sciences
2.06
-1.28
-38.32%
NURO
Neurometrix
4.58
0.88
23.78%
CODX
Co-Diagnostics
0.29
-0.83
-74.11%
PAVM
PAVmed
0.59
-0.43
-42.16%
VVOS
Vivos Therapeutics
5.61
3.21
133.75%

Biomerica Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Biomerica Appoints Eric B. Chin to Board
Positive
Jun 6, 2025

On June 4, 2025, Cathy Coste resigned from Biomerica‘s Board of Directors, and Eric B. Chin was appointed as an independent member, serving as Chairperson of the Audit Committee. Mr. Chin, an experienced financial executive, is expected to strengthen Biomerica’s corporate governance and financial oversight as the company scales its commercialization efforts. His extensive background in healthcare finance, including his role as CFO of Akido Labs, positions him to contribute significantly to Biomerica’s strategic objectives.

Delistings and Listing ChangesStock Split
Biomerica Announces Reverse Stock Split Effective April 21
Neutral
Apr 16, 2025

On April 16, 2025, Biomerica announced a 1-for-8 reverse stock split effective April 21, 2025, to increase the bid price of its common stock and maintain its Nasdaq listing. This move will reduce the number of outstanding shares from approximately 20.4 million to 2.5 million, while the number of authorized shares remains unchanged. The reverse stock split aims to enhance Biomerica’s market position by ensuring compliance with Nasdaq’s minimum bid price requirements.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 03, 2025